1. Patients undergoing PGT-A 2. Patients undergoing PGT-A combined with PGT-M
Conditions
Interventions
Control Group (Optimized Embryo Transfer Following Preimplantation Genetic Testing for Aneuploidy):None
Study Group (Transfer of mosaic embryos classified as "false positive" by the PH-Trace model):None
Sponsors
Chongqing Health Center for Women and Children
Eligibility
Sex/Gender
Female
Age
22 Years to 46 Years
Inclusion criteria
Inclusion criteria: Study Group: 1. The following two categories of populations: (1) Patients undergoing PGT-A (with normal chromosomal karyotypes). (2) Patients undergoing PGT-A combined with PGT-M; 2. Agreement to single blastocyst transfer; 3. Agreement to transfer a mosaic embryo (patients will be enrolled after expressing their willingness to transfer a mosaic embryo). Control Group: 1. The following two categories of populations: (1) Patients undergoing PGT-A (with normal chromosomal karyotypes). (2) Patients undergoing PGT-A combined with PGT-M; 2. Transfer of a single euploid blastocyst during the same study period; 3. Subjects recruited from the same research center as those in the study group; 4. Meet predefined matching candidate criteria: embryo transfer date within 30 days before or after that of the study subject, and maternal age plus AMH levels falling within pre-specified stratified ranges of the study; 5. Subjects satisfying the above control eligibility shall be matched to study subjects via 1:2 nearest-neighbor matching without replacement, and enrolled into the final control group after screening based on predefined standardized distance metrics.
Exclusion criteria
Exclusion criteria: 1. Either or both partners carrying chromosomal structural abnormalities, such as: balanced translocation, Robertsonian translocation, inversion, complex rearrangements, pathogenic microdeletions or microduplications; 2. Uterine anomalies (unicornuate uterus and uterus didelphys), untreated septate uterus, adenomyosis, submucosal leiomyoma, endometrial polyps, or intrauterine adhesions (including history of intrauterine adhesions); 3. Oocyte donation/semen donation/frozen oocyte cycles; 4. Untreated severe hydrosalpinx with evidence of hydrosalpinx fluid reflux into uterine cavity; 5. Uncorrected endocrine disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ongoing pregnancy rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Live birth rate;hCG-positive pregnancy rate;Concordance between PGT-A results and prenatal diagnosis/products of conception testing results;Clinical pregnancy rate;Early miscarriage rate; | — |
Countries
China
Contacts
Public ContactTingting Lin
Chongqing Health Center for Women and Children
Outcome results
None listed